Skin‐infiltrating basophils promote atopic dermatitis‐like inflammation via IL‐4 production in mice
- 13 May 2020
- Vol. 75 (10), 2613-2622
- https://doi.org/10.1111/all.14362
Abstract
Background Patients with atopic dermatitis (AD) often show the infiltration of basophils in the affected skin. Because basophils represent only a minor fraction among cellular infiltrates in the skin lesion, the functional significance of skin‐infiltrating basophils in AD pathogenesis remains ill‐defined. In this study, we aimed to clarify the role of basophils and their effector molecules triggering skin inflammation in oxazolone (OX)‐induced murine model of AD. Methods A panel of mouse strains were sensitized and repeatedly challenged with topical applications of OX to induce AD‐like skin inflammation. Both local and systemic Th2 immune responses were analyzed. Results Basophils progressively accumulated in the skin lesion but barely in draining lymph nodes (LNs). When basophils were depleted during the elicitation phase, skin inflammation was ameliorated while Th2 cell differentiation in draining LNs remained intact. The expression of IL‐4 was highly upregulated in the affected skin, and basophils turned out to be the major producers of IL‐4 among cellular infiltrates, suggesting the involvement of basophil‐derived IL‐4 in the Th2 skin inflammation. Indeed, basophil‐specific IL‐4‐deficient mice displayed attenuated skin inflammation with a marked reduction of IL‐4 in the skin lesion, even though cutaneous basophil infiltration and serum levels of IgE remained intact. Conclusions Skin‐infiltrating basophils promoted OX‐induced AD‐like skin inflammation through their local production of IL‐4, rather than the induction of Th2 cell differentiation in draining LNs. This study suggests that the selective targeting of basophils could be a beneficial strategy in the treatment of a certain type of AD.Funding Information
- Hoyu Science Foundation
This publication has 29 references indexed in Scilit:
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisThe New England Journal of Medicine, 2016
- Genetic and epigenetic studies of atopic dermatitisAllergy, Asthma & Clinical Immunology, 2016
- Basophil recruitment and activation in inflammatory skin diseasesAllergy, 2011
- Th2 Cytokines and Atopic DermatitisAlternative & Integrative Medicine, 2011
- An update on the genetics of atopic dermatitis: Scratching the surface in 2009Journal of Allergy and Clinical Immunology, 2010
- Atopic DermatitisThe New England Journal of Medicine, 2008
- Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitisJournal of Allergy and Clinical Immunology, 2006
- The occurrence of atopic dermatitis in North Europe: An international questionnaire studyJournal of the American Academy of Dermatology, 1996
- Enhanced IL-4 Production and IL-4 Receptor Expression in Atopic Dermatitis and Their Modulation by Interferon-GammaJournal of Investigative Dermatology, 1992